Nighttime home blood pressure was a crucial indicator in predicting adverse outcomes for patients with stage B heart failure
Abstract Body (Do not enter title and authors here): Background: Stage B heart failure (HF) was associated with increased cardiovascular and HF events. Hypertension is a risk factor for these events in Stage B HF. Nighttime blood pressure (BP) is more strongly associated with cardiovascular events than daytime BP, but nighttime home BP measurement is not widely used. Method: We analyzed 573 stage B HF patients with at least one cardiovascular risk factor who underwent home BP monitoring. Stage B HF was defined as BNP ≥35pg/ml, or NT-proBNP ≥125pg/ml, Troponin T >0.014ng/ml, LVEF <50%, enlarged left ventricular dimensions in diastole (≥60mm in men and ≥54mm in women), enlarged left atrium (>40mm), or increased left ventricular mass (>115g/m2 in men and >95g/m2 in women). Morning, evening, and nighttime home BP were measured by home BP devices, and cardiovascular events were followed up. Results: During a mean follow-up of 7.6 ± 3.6 years, 65 cardiovascular events occurred. Morning, evening, and nighttime home SBP were higher in the event group than in the non-event group (146±19 vs 140±14 mmHg, p=0.01, 137±17 vs 131±14 mmHg, p<0.01, 129±16 vs 123±14 mmHg, p<0.01, respectively). Kaplan Meier analysis showed that the high BP cut-off group defined by HT guidelines had significantly higher incidents of events in office, morning, and nighttime home SBP (p=0.03, p=0.02, p<0.01, respectively)(Figure). In multivariate Cox regression analysis adjusting for significant variables, nighttime home SBP >120mmHg was a significant predictor of the outcome (Hazard Ratio 2.03, 95% Confidence Interval: 1.13-3.65, p=0.02). Conclusions: Elevated nighttime home BP was a significant predictor for cardiovascular outcomes in stage B HF patients.
Komori, Takahiro
( Jichi Medical University
, Tochigi-ken
, Japan
)
Hoshide, Satoshi
( JICHI MIDICAL UNIVERSITY
, Shimotsuke
, Japan
)
Kario, Kazuomi
( JICHI MEDICAL UNIVERSITY
, Tochigi-ken
, Japan
)
Author Disclosures:
Takahiro Komori:DO NOT have relevant financial relationships
| Satoshi Hoshide:DO NOT have relevant financial relationships
| Kazuomi Kario:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Omuron Healthcare Co. Ltd.:Active (exists now)
; Research Funding (PI or named investigator):A&D Co Ltd.:Active (exists now)
; Research Funding (PI or named investigator):Fukuda Denshi Co. Ltd.:Active (exists now)
Tran Dieu Hien, Do Chau, Nguyen Thi Kim Chuc, Pham Ngoc Anh Vu, Phan Hoang Son, Phan Tri Cuong, Han Nguyen Le My, Nguyen Thi Huong Dung, Vo Le Y Nhi, Cao Doan Thi Bich Huyen, Tran Thanh Phong, Truyen Thien Tan Tri Tai, Tran Van Duong, Nguyen Ngoc Huyen, Pham Thanh Phong, Nguyen Minh Nghiem, Nguyen Van Khoa, Vo Phuc Dai, Le Hoang Phuc, Dinh Quang Minh Trí, Vu Loc, Kieu Doan Thi